Abstract: An improved method and apparatus using a newly defined nonlinear technology that more accurately describes the biological process of dose titration to calculate next agent dose(s) in single and multi-agent therapy. The overall proportion of each agent is determined by the amount of agent as it relates to the dosing range. The overall proportion as well as the intrinsic potency of the agent is used to determine the total proportional effect that each agent has on the surrogate marker. This parameter is then inserted into the four-parameter equation for calculating dose by adjusting the proportional change in marker that is attributed to the activity of the agent.

Abstract: An improved method and apparatus using a newly defined nonlinear technology that more accurately describes the biological process of dose titration to calculate next agent dose(s) in single and multi-agent therapy. The overall proportion of each agent is determined by the amount of agent as it relates to the dosing range. The overall proportion as well as the intrinsic potency of the agent is used to determine the total proportional effect that each agent has on the surrogate marker. This parameter is then inserted into the four-parameter equation for calculating dose by adjusting the proportional change in marker that is attributed to the activity of the agent.

Abstract: A method, apparatus and system for use in treating a patient receiving an antineoplastic drug to optimize therapy and prevent an adverse drug response. This system employs surrogate markers or indicators including blood levels of the antineoplastic drug to determine the next required dose for a patient. Since the surrogate markers are employed as a percent change in status, virtually any indicator can be used. Surrogate markers could include any measure of the effectiveness of the antineoplastic drug's action. Given the effectiveness of the antineoplastic drug's action relative to the surrogate markers, a change in antineoplastic drug dose is calculated by the system. Conversely, by employing this system, one could determine the expected result of the antineoplastic drug dose change on the surrogate markers.

Abstract: A method, system and apparatus for use in treating a patient receiving a biological substance, such as a cancer vaccine, to optimize therapy and prevent an adverse response. This system employs surrogate markers or indicators including blood levels of the vaccine to determine the next required dose for a patient. Since the surrogate markers may be employed as a percent change in status, virtually any indicator can be used. Surrogate markers could include any measure of the effectiveness of the vaccine's action. Given the effectiveness of the vaccine's action relative to the surrogate markers, a change in vaccine dose is calculated by the system. Conversely, by employing this system, one could determine the expected result of the vaccine dose change on the surrogate markers.

Abstract: A method and apparatus using IDS™ technology to calculate new agent doses in a multi-agent therapy. The overall proportion of each agent is determined by the amount of agent as it relates to the dosing range. The overall proportion as well as the intrinsic potency of the agent is used to determine the total proportional effect which each agent has on the surrogate marker. This parameter is then inserted into the four-parameter equation for calculating dose by adjusting the proportional change in marker that is attributed to the activity of the agent.

Abstract: A method and system for use in treating a patient receiving any drug to optimize therapy and to prevent an adverse drug response. This system employs surrogate markers or indicators, including blood levels of drug, to determine the next required dose for a patient. Virtually any indicator can be used as the surrogate marker. Surrogate markers could include any measure of the effectiveness of a drug's action. Given the effectiveness of the drug's action, relative to the surrogate markers, a change in drug dose is calculated by the system which uses a stochastic loop mechanism. Conversely, by employing this system, one could determine the expected result of a drug dose change based on the surrogate markers.

Abstract: A method and apparatus using IDS™ technology to calculate new agent doses in a multi-agent therapy. The overall proportion of each agent is determined by the amount of agent as it relates to the dosing range. The overall proportion as well as the intrinsic potency of the agent is used to determine the total proportional effect which each agent has on the surrogate marker. This parameter is then inserted into the four-parameter equation for calculating dose by adjusting the proportional change in marker that is attributed to the activity of the agent.

Abstract: A method, system and apparatus for use in treating a patient receiving a biological substance, such as a cancer vaccine, to optimize therapy and prevent an adverse response. This system employs surrogate markers or indicators including blood levels of the vaccine to determine the next required dose for a patient. Since the surrogate markers may be employed as a percent change in status, virtually any indicator can be used. Surrogate markers could include any measure of the effectiveness of the vaccine's action. Given the effectiveness of the vaccine's action relative to the surrogate markers, a change in vaccine dose is calculated by the system. Conversely, by employing this system, one could determine the expected result of the vaccine dose change on the surrogate markers.

Abstract: A method and system for use in treating a patient receiving any drug to optimize therapy and to prevent an adverse drug response. This system employs surrogate markers or indicators, including blood levels of drug, to determine the next required dose for a patient. Virtually any indicator can be used as the surrogate marker. Surrogate markers could include any measure of the effectiveness of a drug's action. Given the effectiveness of the drug's action, relative to the surrogate markers, a change in drug dose is calculated by the system which uses a stochastic loop mechanism. Conversely, by employing this system, one could determine the expected result of a drug dose change based on the surrogate markers.

Abstract: A method, apparatus and system for use in treating a patient receiving an antineoplastic drug to optimize therapy and prevent an adverse drug response. This system employs surrogate markers or indicators including blood levels of the antineoplastic drug to determine the next required dose for a patient. Since the surrogate markers are employed as a percent change in status, virtually any indicator can be used. Surrogate markers could include any measure of the effectiveness of the antineoplastic drug's action. Given the effectiveness of the antineoplastic drug's action relative to the surrogate markers, a change in antineoplastic drug dose is calculated by the system. Conversely, by employing this system, one could determine the expected result of the antineoplastic drug dose change on the surrogate markers. This document may contain material which is the subject of copyright protection. All rights in such copyrightable material are hereby reserved.

Abstract: A method and system for use in treating a patient with FK 506 to prevent an adverse immune response, either a rejection of a transplanted organ or an attack on the patient's body by its own immune system caused by an autoimmune disease, without unduly suppressing the ability of the patient's immune system to combat infection. The method employs an expert system to provide non-numerical information concerning the course of action to be taken with respect to a patient's FK 506 treatment, at a given time, including, in particular, an instruction on whether the FK 506 dosage being administered to the patient should be changed, and if so how. That instruction is determined by the expert system through analysis of standardized characterizations assigned to standardized patient examination criteria provided to the expert system. The method also determines the actual numerical FK 506 dosage the patient should receive at a given time.

Abstract: A method and system for use in treating a patient with FK 506 to prevent an adverse immune response, either a rejection of a transplanted organ or an attack on the patient's body by its own immune system caused by an autoimmune disease, without unduly suppressing the ability of the patient's immune system to combat infection. The method employs an expert system to provide non-numerical information concerning the course of action to be taken with respect to a patient's FK 506 treatment, at a given time, including, in particular, an instruction on whether the FK 506 dosage being administered to the patient should be changed, and if so how. That instruction is determined by the expert system through analysis of standardized characterizations assigned to standardized patient examination criteria provided to the expert system. The method also employs a means for determining the actual numerical FK 506 dosage the patient should receive at a given time.